钠-葡萄糖协同转运蛋白2抑制剂用药安全性研究进展

Research Progress on the Safety of Sodium and Glucose Co-Transporter 2 Inhibitors

目的了解钠-葡萄糖协同转运蛋白2抑制剂(SGLT-2i)安全性的研究进展,为其合理应用提供参考。方法查阅近年来国内外相关文献,总结SGLT-2i使用中的不良反应。结果 SGLT-2i的不良反应主要有低血糖、泌尿生殖道感染、低血压等,但发生率不高,且特殊人群用药尚不完全明确。结论 SGLT-2i上市时间较短,仍需长期的临床实践证实其不良反应的相关性及在特殊人群中应用的安全性。

Objective To understand the research progress of the safety of sodium and glucose co-transporter 2 inhibitors（SC, LT-2i） and provide a reference for their clinical application. Methods The related literatures at home and abroad in recent years were reviewed and the adverse reactions in the use of SGLT-2i were summarized. Results The adverse reactions of SGLT-2i were mainly hypoglycemia, genitourinary infection, hypotension, etc.,but the incidence rate was low. The use of drugs in special populations was not completely clear. Conclusion The market for SGLT-2i is short, and long-term clinical trials are needed to confirm the relevance of adverse reactions and the safety of application in special populations.